Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25399580 | 0.98 | CYP1A2 (0.55) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL26186830 | 0.94 | CYP1A2 (0.60) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL10318724 | 0.85 | ACHE (0.54) | ACHE | |
| SCHEMBL8863154 | 0.79 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19ACHE | |
| SCHEMBL6777483 | 0.79 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19ACHE | |
| SCHEMBL8863094 | 0.79 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19ACHE | |
| SCHEMBL8862878 | 0.79 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19ACHE | |
| SCHEMBL8862728 | 0.79 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19ACHE | |
| SCHEMBL2604742 | 0.79 | TDP1 (0.75) | TDP1L3MBTL1CYP1A2CYP2C19ACHE | |
| SCHEMBL9084215 | 0.77 | CYP1A2 (0.88) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2459228-B1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI AVENTIS DEUTSCHLAND (DE) | 2020-03-04 | — | — | EP | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | ASCENDIS PHARMA A/S (DK) | 2017-08-10 | — | — | US | disclosed |
| EP-2459171-B1 | Long acting insulin composition | SANOFI AVENTIS DEUTSCHLAND (DE) | 2017-06-21 | — | — | EP | disclosed |
| US-9457066-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-10-04 | — | — | US | disclosed |
| US-9265723-B2 | Long acting insulin composition | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2016-02-23 | — | — | US | disclosed |
| WO-2016020373-A1 | PRODRUGS COMPRISING AN AMINOALKYL GLYCINE LINKER | ASCENDIS PHARMA A/S (DK) | 2016-02-11 | — | — | WO | disclosed |
| US-9138462-B2 | Prodrugs comprising an insulin linker conjugate | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-22 | — | — | US | disclosed |
| US-20150258207-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2015-09-17 | — | — | US | disclosed |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2012-07-19 | — | — | US | disclosed |
| EP-2459228-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | Sanofi-Aventis Deutschland GmbH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | ASCENDIS PHARMA AS (DK) | 2012-03-08 | — | — | US | disclosed |
| WO-2011012718-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010100220-A1 | INTERFERON ALPHA CARRIER PRODRUGS | ASCENDIS PHARMA AS (DK) | 2010-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150258207-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | TDP1 3259/4885L3MBTL1 104/4885CYP1A2 1339/4885 |
| US-20170224829-A1 | Prodrugs Comprising an Aminoalkyl Glycine Linker | DNPEP, PAM, ASNS | TDP1 1621/4885L3MBTL1 2318/4885CYP1A2 535/4885 |
| US-20120184489-A1 | PRODRUGS COMPRISING AN INSULIN LINKER CONJUGATE | IAPP, IGF1R, INSR | TDP1 3259/4885L3MBTL1 104/4885CYP1A2 1339/4885 |
| US-20120183616-A1 | LONG ACTING INSULIN COMPOSITION | IAPP, INSR, GPR119 | TDP1 4721/4885L3MBTL1 4730/4885CYP1A2 1807/4885 |
| US-20120058084-A1 | Interferon Alpha Carrier Prodrugs | IFNG, IFNAR1, IRF3 | TDP1 1973/4885L3MBTL1 3830/4885CYP1A2 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.